Xenon Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
Date: December 2, 2019
Company: Xenon Pharmaceuticals Inc. (XENE)
Event: Entry into a Material Definitive Agreement (License and Collaboration) and Unregistered Sales of Equity Securities with Neurocrine Biosciences, Inc.
Xenon entered into a strategic collaboration to identify, research, and develop sodium channel inhibitors, including clinical candidate XEN901 and preclinical candidates XEN393, XPC'535, and XPC'391. Neurocrine received exclusive rights to further develop and commercialize these compounds worldwide.
Key Financial Metrics and Transaction Terms
Upfront Consideration: $50.0 million total.
- Cash: $30.0 million (payable within 10 business days).
- Equity: $20.0 million via private placement of 1,408,847 common shares at $14.196/share (20% premium to Nov 29, 2019 close).
Future Milestone Payments (Potential):
- IND Acceptance Milestones: Up to $11.25 million cash + $13.75 million equity (SCN8A-EE) or $4.5 million cash + $5.5 million equity (Major Indication).
- Development/Regulatory Milestones: Up to $325.0 million for XEN901; up to $247.5 million per other Compound (max 3 compounds).
- Sales Milestones: Up to $150.0 million per Compound (max 4 compounds).
Royalties: Tiered percentages on Net Sales ranging from mid-single digit to mid-teen percentages, varying by compound and geography (US vs. Non-US).
Liquidity Outlook: Management anticipates sufficient cash to fund operations into 2022, supporting planned clinical development of XEN1101, XEN496, and XEN007, excluding other potential revenue.
Material Changes and Strategic Developments
- Collaboration Structure: Establishment of a Joint Steering Committee (JSC) to oversee a Research Program (2-year term) and an Initial Development Program for XEN901 and two selected preclinical candidates.
- Equity Issuance: Neurocrine purchased shares subject to a 2-year lock-up and a 2-year standstill agreement regarding control of Xenon.
- Regulatory Progress (XEN496): FDA granted Orphan Drug Designation for XEN496 (ezogabine) for KCNQ2-DEE. A PK study in healthy adults is planned for Q1 2020, with an IND filing expected in Q1 2020 to discuss Phase 3 trial design.
- Regulatory Progress (XEN901): Neurocrine anticipates filing an IND with the FDA in mid-2020 for a clinical trial in SCN8A-DEE patients.
Guidance, Risks, and Contingencies
Management Commentary: The transaction extends Xenon's cash runway into 2022. Neurocrine assumes primary responsibility for development, regulatory activities, and commercialization of the licensed compounds.
Risks and Contingencies:
- Termination: Neurocrine may terminate the agreement for any reason with 90 days' notice, subject to completing specific Phase 1 or Phase 2 clinical trials for XEN901 and DTCs.
- Co-Funding Option: Xenon has the right to co-fund development of one product in a "Major Indication" in exchange for a mid-single digit royalty increase.
- Voucher Rights: If a Rare Pediatric Disease Priority Review Voucher is granted for XEN901, Neurocrine may sell it or use it, with proceeds or value shared with Xenon under specific conditions.
- Forward-Looking Statements: Timelines for IND filings, clinical trials, and cash runway are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the closing of the $30.0 million cash payment and the issuance of 1,408,847 shares to Neurocrine.
- Monitor the timeline for Neurocrine's IND filing for XEN901 (anticipated mid-2020) and Xenon's IND filing for XEN496 (anticipated Q1 2020).
- Review the specific definitions of "Major Indication" and "SCN8A-EE" to understand the triggers for the $11.25M/$4.5M milestone payments.
- Assess the impact of the 2-year standstill agreement on potential future M&A activity or control changes.
- Track the progress of the Joint Steering Committee in selecting the two DTCs for the Initial Development Program.